Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME

Key Points

• Assenagon Asset Management increased its Zymeworks stake by 72% in the second quarter, adding 524,041 shares for a total holding worth approximately $32.7 million. Institutional investors now own 92.89% of the company.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $38.22, compared with shares recently trading near $23.54.
• Zymeworks reported a wider-than-expected quarterly loss of $0.62 per share and a 90.6% year-over-year revenue decline, despite revenue slightly exceeding estimates. The company also has authorization to repurchase up to $125 million, or 7%, of its shares.

Assenagon Asset Management S.A. increased its position in shares of Zymeworks Inc. (NASDAQ:ZYME - Free Report) by 72.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,252,027 shares of the company's stock after purchasing an additional 524,041 shares during the period. Assenagon Asset Management S.A. owned approximately 1.71% of Zymeworks worth $32,728,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new position in Zymeworks during the 4th quarter worth $37,000. Quarry LP bought a new position in Zymeworks during the third quarter worth about $50,000. Tower Research Capital LLC TRC raised its stake in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company's stock worth $62,000 after purchasing an additional 1,131 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Zymeworks by 25.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company's stock valued at $96,000 after purchasing an additional 731 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Zymeworks by 157.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company's stock valued at $129,000 after purchasing an additional 6,307 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a research report on Friday. Wells Fargo & Company increased their price target on Zymeworks from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Friday. Truist Financial raised their price objective on Zymeworks from $31.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday. Citigroup reaffirmed a "buy" rating on shares of Zymeworks in a report on Tuesday, June 30th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Zymeworks in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.22.

Zymeworks Price Performance

Shares of ZYME opened at $23.54 on Friday. Zymeworks Inc. has a one year low of $11.51 and a one year high of $29.75. The company has a market cap of $1.72 billion, a P/E ratio of -11.65 and a beta of 1.15. The firm has a 50 day simple moving average of $23.99 and a two-hundred day simple moving average of $24.45.

Zymeworks (NASDAQ:ZYME - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06). Zymeworks had a negative net margin of 405.31% and a negative return on equity of 60.02%. The business had revenue of $4.59 million during the quarter, compared to analyst estimates of $4.54 million. During the same period in the prior year, the business posted $0.03 EPS. The company's revenue for the quarter was down 90.6% compared to the same quarter last year. On average, analysts expect that Zymeworks Inc. will post 1.25 earnings per share for the current fiscal year.

Zymeworks declared that its board has approved a share repurchase program on Thursday, May 14th that authorizes the company to repurchase $125.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 7% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Truist raises target and maintains a Buy rating: Truist Financial lifted its price target from $31 to $32, implying substantial upside from recent trading levels. The firm’s continued Buy recommendation may support investor confidence. Benzinga article
• Positive Sentiment: Analysts remain broadly bullish: HC Wainwright reiterated its Buy rating and $51 price target, while a separate brokerage report cited an average price target of $37.33. These targets suggest analysts see meaningful long-term value in Zymeworks despite near-term losses. Average price target article
• Neutral Sentiment: Revenue exceeded expectations: Zymeworks reported quarterly revenue of $4.59 million, ahead of the $3.81 million consensus estimate. However, the company remains unprofitable, limiting the positive impact of the revenue beat. Zacks earnings article
• Negative Sentiment: Quarterly loss was wider than expected: Zymeworks posted a loss of $0.62 per share, missing estimates for a $0.56–$0.57 loss and reversing year-earlier earnings of $0.03 per share. Revenue also declined 90.6% year over year, while the company reported a negative net margin and return on equity. Zymeworks earnings release
• Negative Sentiment: HC Wainwright cut earnings forecasts: The firm reduced its FY2026 EPS estimate from $1.00 to $0.36 and lowered its Q2 and Q4 forecasts to losses of $0.58 and $0.54 per share, respectively. It also trimmed its Q3 estimate to $2.09 from $2.17, signaling weaker near-term earnings expectations.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks' innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source